Background:
Current treatments for SARS-CoV-2 rely on direct-acting antivirals including the 3CLpro inhibitor nirmatrelvir/r (NMV/r) and the mutagenic nucleoside analog molnupiravir (MOV). There have been concerns regarding the use of MOV including the generation of new viral variants. In a previous study, we compared the antiviral effect of MOV or NMV/r alone, or the co-administration of both in a SARS-CoV-2 macaque model. We showed an additive effect of the two antivirals on several markers of disease. In this follow-up study, we investigated the mutation profiles of SARS-CoV-2 in samples collected in the previous study.
Methods:
Twenty macaques received the oral treatment of MOV, NMV/r, combination therapy or vehicle control (5 in each group) starting 12 hours after exposure to SARS-CoV-2, and they were followed for 4 days before necropsy. Viral RNA was extracted from lung tissue samples at necropsy. Primer ID sequencing approach was used to sequence nsp5 (3CLpro), a portion nsp12 (RdRp) and the S gene receptor binding domain (S-RBD). Substitutions with a FDR-adjusted p value of less than 0.05 were considered as true mutations. This work was partially funded by the Intramural Research Program, NIAID.
Results:
In the MOV group, the overall substitution rate was approx. 0.05%, significantly higher than other groups. The mutation profile was driven by the increase of C-to-U and G-to-A mutations. The overall substitution rates were significantly increased in the MOV+NMV/r group compared with NMV/r or vehicle groups, but lower than MOV group (Fig 1A). We further studied the impact of MOV on the potential development of resistance mutations on 3CLpro against NMV. We did not observe any mutation hotspots in this region beyond those mediated by MOV. Mutations identified in the MOV group were largely distinct in frequency from those in the combination group. We assessed the amino acid codon changes at four positions (L50F, E166A, E166V, and L167F) that have been reported to contribute to NMV resistance. We did observe an increase in the abundance of L50F in the MOV group but it was not further enriched in the combination group (Fig 1B).
Conclusions:
Our results suggest that co-administration of NMV/r lowered the magnitude of the mutagenetic effect of MOV against SARS-CoV-2, likely due to the additive effect of the combination therapy on reduced rounds of viral replication. There is no evidence that combination therapy potentiated selection for NMV resistance mutations during 4 days of treatment.
![]()